唑来膦酸联合苦参碱治疗晚期前列腺癌骨转移的疗效

Efficacy of zoledronic acid combined with matrine in patients with bone metastases of advanced prostate cancer

目的 评价唑来膦酸联合苦参碱治疗晚期前列腺癌骨转移的临床疗效.方法 79例晚期前列腺癌并发骨转移患者,随机分为两组,治疗组44例患者采用唑来膦酸联合苦参碱静脉滴注,对照组患者35例单纯给予唑来膦酸静脉滴注,治疗3个月后评价两组患者骨痛缓解率及骨转移情况.结果 治疗组与对照组血碱性磷酸酶（ALP）水平均较治疗前出现改变,治疗组血ALP较对照组明显降低,两组比较差异有统计学意义（P＜0.05）.治疗组与对照组的疼痛缓解率分别88.64％（39/44）与62.86％（22/35）,疼痛缓解率差异有统计学意义（P＜0.05）.结论 唑来膦酸联合苦参碱治疗晚期前列腺癌骨转移可较好的缓解疼痛并减低骨代谢水平.

Objective To evaluate the clinic efficacy of zoledronic acid combined with matrine in the treatment of advanced prostate with bone metastases.Methods A total of 79 patients with advanced prostate cancer were randomly divided into two groups,treatment group （44 cases） received the therapy of zoledronic acid combined with matrine,control group （35 cases） accepted the zoledronic acid treatment simply.Serum ALP values and visual analogue pain score （VAS） were evaluated 3 months after treatment.Results The levels of ALP in the treatment group and the control group were changed compared with those before treatment,the blood ALP in the treatment group was significantly lower than that in the control group,the difference between the two groups was statistically significant （P ＜0.05）.The total efficiency of pain relief was 88.64％ in treatment group,and 62.86％ in the control group,it was significant difference between the two groups （P ＜ 0.05）.Conclusions Zoledronic acid combined with matrine in the treatment of advanced prostate cancer with bone metastasis can relieve pain and reduce bone metabolism.